Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 4/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.34 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.34 |
| ▸ | CHRM2 | P08172 | 2/20 | 0.33 |
| ▸ | CHRM4 | P08173 | 2/20 | 0.33 |
| ▸ | CHRM5 | P08912 | 2/20 | 0.33 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.33 |
| ▸ | CHRM3 | P20309 | 2/20 | 0.33 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.32 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.32 |
| ▸ | APEX1 | P27695 | 1/20 | 0.32 |
| ▸ | THPO | P40225 | 1/20 | 0.32 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1578051 | 0.79 | TSHR (0.40) | TSHRALDH1A1RAB9AEPHX2LMNA | |
| SCHEMBL294716 | 0.77 | LMNA (0.43) | ALDH1A1LMNAMEN1CYP3A4CYP2C9 | |
| SCHEMBL1297720 | 0.74 | TSHR (0.45) | TSHRALDH1A1RAB9AEPHX2LMNA | |
| SCHEMBL294867 | 0.73 | PPM1B (0.42) | ALDH1A1EPHX2 | |
| SCHEMBL7104141 | 0.73 | ALDH1A1 (0.50) | TSHRALDH1A1RAB9ALMNAHSP90AA1 | |
| SCHEMBL11037512 | 0.73 | TSHR (0.34) | TSHRALDH1A1RAB9AEPHX2LMNA | |
| SCHEMBL1297889 | 0.72 | TSHR (0.43) | TSHRALDH1A1RAB9AEPHX2LMNA | |
| SCHEMBL6141274 | 0.72 | ADRB2 (0.45) | TSHRALDH1A1RAB9ALMNACHRM2 | |
| SCHEMBL27296220 | 0.72 | TSHR (0.43) | TSHRALDH1A1RAB9AEPHX2LMNA | |
| SCHEMBL1196568 | 0.72 | ADRB2 (0.45) | TSHRALDH1A1RAB9ALMNACHRM2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | MATIER WILLIAM L (US) | 2013-05-23 | — | — | US | disclosed |
| EP-1683783-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-1683782-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-1120402-B1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO (JP) | 2008-06-25 | — | — | EP | disclosed |
| EP-1683782-A2 | Chiral copper complex and production processes thereof and using the same | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
| EP-1683783-A2 | Chiral copper complex and production processes thereof and using the same | Sumitomo Chemical Company, Limited (JP) | 2006-07-26 | — | — | EP | disclosed |
| US-7009079-B2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2006-03-07 | — | — | US | disclosed |
| US-20050090684-A1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL CO., LTD. | 2005-04-28 | — | — | US | disclosed |
| US-6670500-B2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2003-12-30 | — | — | US | disclosed |
| US-6469198-B2 | OBTAINED BY CONTACTING N-SALICYLIDENEAMINOALCOHOL WITH MONO OR DIVALENT COPPER COMPOUND; FORMATION OF OPTICALLY ACTIVE CYCLOPROPANE-CARBOXYLIC ESTER FROM PROCHIRAL OLEFIN AND DIAZOACETIC ACID ESTER | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-10-22 | — | — | US | disclosed |
| US-20020004618-A1 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2002-01-10 | — | — | US | disclosed |
| US-20010037036-A1 | Chiral copper complex catalyst composition and asymmetric production process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-11-01 | — | — | US | disclosed |
| EP-1120402-A2 | Chiral copper complex and production processes thereof and using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-01 | — | — | EP | disclosed |
| EP-1120401-A2 | Chiral copper complex catalyst composition and asymmetric production process using the same | SUMITOMO CHEMICAL COMPANY, LIMITED (JP) | 2001-08-01 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050090684-A1 | Chiral copper complex and production processes thereof and using the same | SOD1, CYP1A1, NFXL1 | TSHR 1375/4885ALDH1A1 16/4885RAB9A 3308/4885 |
| US-20010037036-A1 | Chiral copper complex catalyst composition and asymmetric production process using the same | AP1M1, UBA3, AP1S1 | TSHR 4320/4885ALDH1A1 254/4885RAB9A 2923/4885 |
| US-20130131052-A1 | Amelioration Of The Development Of Cataracts And Other Ophthalmic Diseases | C3AR1, C1R, AKR1C3 | TSHR 246/4885ALDH1A1 756/4885RAB9A 866/4885 |
| US-20020004618-A1 | Chiral copper complex and production processes thereof and using the same | SOD1, XDH, NFXL1 | TSHR 2499/4885ALDH1A1 19/4885RAB9A 3043/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.